Recurrent Linear Dermatosis in a 9-Year-Old Boy

International audienc

Merkel Cell Polyomavirus Strains in Patients with Merkel Cell Carcinoma

We investigated whether Merkel cell carcinoma (MCC) patients in France carry Merkel cell polyomavirus (MCPyV) and then identified strain variations. All frozen MCC specimens and 45% of formalin-fixed and paraffin-embedded specimens, but none of the non-MCC neuroendocrine carcinomas specimens, had MCPyV. Strains from France and the United States were similar

A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

BACKGROUND: Oral ivermectin is a safe broad spectrum anthelminthic used for treating several neglected tropical diseases (NTDs). Currently, ivermectin use is contraindicated in children weighing less than 15 kg, restricting access to this drug for the treatment of NTDs. Here we provide an updated systematic review of the literature and we conducted an individual-level patient data (IPD) meta-analysis describing the safety of ivermectin in children weighing less than 15 kg. METHODOLOGY/PRINCIPAL FINDINGS: A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for IPD guidelines by searching MEDLINE via PubMed, Web of Science, Ovid Embase, LILACS, Cochrane Database of Systematic Reviews, TOXLINE for all clinical trials, case series, case reports, and database entries for reports on the use of ivermectin in children weighing less than 15 kg that were published between 1 January 1980 to 25 October 2019. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515. A total of 3,730 publications were identified, 97 were selected for potential inclusion, but only 17 sources describing 15 studies met the minimum criteria which consisted of known weights of children less than 15 kg linked to possible adverse events, and provided comprehensive IPD. A total of 1,088 children weighing less than 15 kg were administered oral ivermectin for one of the following indications: scabies, mass drug administration for scabies control, crusted scabies, cutaneous larva migrans, myiasis, pthiriasis, strongyloidiasis, trichuriasis, and parasitic disease of unknown origin. Overall a total of 1.4% (15/1,088) of children experienced 18 adverse events all of which were mild and self-limiting. No serious adverse events were reported. CONCLUSIONS/SIGNIFICANCE: Existing limited data suggest that oral ivermectin in children weighing less than 15 kilograms is safe. Data from well-designed clinical trials are needed to provide further assurance

Low-frequency ultrasound sonophoresis applied to humans in vivo.

Introduction. Les ultrasons (US) basse fréquence appliqués sur la peau pour en augmenter laperméabilité (sonophorèse) peuvent promouvoir le passage transcutané de molécules in vitroet in vivo chez l’animal. L’objectif de ce travail a été d’appliquer la sonophorèse à l’homme invivo.Méthodes. Trois essais cliniques randomisés ont été menés chez le volontaire sain : l’essai (1)évaluant la tolérance des US à différentes intensités versus placebo ; l’essai (2) évaluant lapénétration transcutanée de l’histamine après sonophorèse ; l’essai (3) comparant l’effetvasoconstricteur d’un dermocorticoïde sans et après sonophorèse. Les US étaient délivrés enmode pulsé, avec une sonde de 36 kHz, durant 5 minutes, à des intensités de 1,57 à 3,50W/cm2.Résultats. Dans l’essai (1), aucune toxicité (douleur > 40/100 ou nécrose) n’a été observéechez les 34 sujets inclus. Les effets secondaires étaient un érythème, et des acouphènesrégressifs dès l’arrêt des US. Dans l’essai (2), l’histamine a induit une papule chez 9/10 sujets,uniquement sur les zones préalablement traitées par US. Dans l’essai (3), sur les 15 sujets, lavasoconstriction induite par le dermocorticoïde était significativement plus importante sur leszones traitées par US, surtout avec une occlusion longue (2h).Conclusions. Ces essais démontrent qu’avec des intensités ultrasonores bien tolérées chezl’homme, la sonophorèse est efficace pour faire pénétrer l’histamine et améliorer l’efficacitédes dermocorticoïdes.Introduction. Low-frequency ultrasound (US) applied on skin, called sonophoresis, havebeen investigated to enhance the transdermal transport of various drugs in vitro and in vivo inanimals. We aimed to investigate low-frequency sonophoresis in vivo in humans.Methods. Three randomized clinical trials have been conducted in healthy subjects: trial (1)aimed to assess skin toxicity of sonophoresis at different intensity levels compared to placebo;trial (2) aimed to investigate the transdermal penetration of histamine with sonophoresis; trial(3) aimed to investigate the clinical efficiency of sonophoresis in enhancing transdermalpenetration of topical steroids in human skin. US were applied in pulsed mode for 5 minutes,with a 36 kHz device. US intensities ranged from 1.57 to 3.50 W/cm2.Results. In trial (1), no toxicity, defined as a pain score > 40/100 or necrosis, was reported.The most frequent adverse events were erythema, and tinnitus, which ceased ondiscontinuation of US. In trial (2), arm zones without US showed no papules, whereas 9/10subjects receiving US showed papules. In trial (3), including 15 subjects, vasoconstrictionwas significantly higher with the topical steroid applied after US than without US, especiallyin the zone with 2-h occlusion.Conclusions. These clinical trials provide favourable exploratory results regarding toleranceof low-frequency sonophoresis on human skin in vivo. They confirm that sonophoresisenhances transdermal penetration of histamine and increases the efficiency of topical steroids

Cutaneous consequences of environmental changes

National audienceThe skin is normally well protected against a majority of substances. Ultraviolet rays play an essential role in the occurrence of cancer and skin aging. There are numerous pollutants, which act on the skin or enter the body through the skin. The new lifestyle entails new risks. We must be vigilant but also avoid unjustified peremptory opinions scientifically unproven

Intérêt de l'immunomarquage par l'anticorps anti-desmogléine dans le diagnostic des pemphigus autoimmun, médicamenteux et paranéoplasique

TOURS-BU Médecine (372612103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Applications de la sonophorèse basse fréquence à l'humain in vivo.

Introduction. Les ultrasons (US) basse fréquence appliqués sur la peau pour en augmenter laperméabilité (sonophorèse) peuvent promouvoir le passage transcutané de molécules in vitroet in vivo chez l animal. L objectif de ce travail a été d appliquer la sonophorèse à l homme invivo.Méthodes. Trois essais cliniques randomisés ont été menés chez le volontaire sain : l essai (1)évaluant la tolérance des US à différentes intensités versus placebo ; l essai (2) évaluant lapénétration transcutanée de l histamine après sonophorèse ; l essai (3) comparant l effetvasoconstricteur d un dermocorticoïde sans et après sonophorèse. Les US étaient délivrés enmode pulsé, avec une sonde de 36 kHz, durant 5 minutes, à des intensités de 1,57 à 3,50W/cm2.Résultats. Dans l essai (1), aucune toxicité (douleur > 40/100 ou nécrose) n a été observéechez les 34 sujets inclus. Les effets secondaires étaient un érythème, et des acouphènesrégressifs dès l arrêt des US. Dans l essai (2), l histamine a induit une papule chez 9/10 sujets,uniquement sur les zones préalablement traitées par US. Dans l essai (3), sur les 15 sujets, lavasoconstriction induite par le dermocorticoïde était significativement plus importante sur leszones traitées par US, surtout avec une occlusion longue (2h).Conclusions. Ces essais démontrent qu avec des intensités ultrasonores bien tolérées chezl homme, la sonophorèse est efficace pour faire pénétrer l histamine et améliorer l efficacitédes dermocorticoïdes.Introduction. Low-frequency ultrasound (US) applied on skin, called sonophoresis, havebeen investigated to enhance the transdermal transport of various drugs in vitro and in vivo inanimals. We aimed to investigate low-frequency sonophoresis in vivo in humans.Methods. Three randomized clinical trials have been conducted in healthy subjects: trial (1)aimed to assess skin toxicity of sonophoresis at different intensity levels compared to placebo;trial (2) aimed to investigate the transdermal penetration of histamine with sonophoresis; trial(3) aimed to investigate the clinical efficiency of sonophoresis in enhancing transdermalpenetration of topical steroids in human skin. US were applied in pulsed mode for 5 minutes,with a 36 kHz device. US intensities ranged from 1.57 to 3.50 W/cm2.Results. In trial (1), no toxicity, defined as a pain score > 40/100 or necrosis, was reported.The most frequent adverse events were erythema, and tinnitus, which ceased ondiscontinuation of US. In trial (2), arm zones without US showed no papules, whereas 9/10subjects receiving US showed papules. In trial (3), including 15 subjects, vasoconstrictionwas significantly higher with the topical steroid applied after US than without US, especiallyin the zone with 2-h occlusion.Conclusions. These clinical trials provide favourable exploratory results regarding toleranceof low-frequency sonophoresis on human skin in vivo. They confirm that sonophoresisenhances transdermal penetration of histamine and increases the efficiency of topical steroids.TOURS-Bibl.électronique (372610011) / SudocSudocFranceF

Carcinome de Merkel et Polyomavirus de Merkel (séroprévalence du virus et détection virale par PCR, avec comparaison à un groupe témoin)

TOURS-BU Médecine (372612103) / SudocSudocFranceF

Traitement par infliximab dans l'hidrosadénite suppurée (amélioration de la qualité de vie dans une série de 7 cas)

TOURS-BU Médecine (372612103) / SudocSudocFranceF

Congenital Melanotic Macules of the Tongue

International audienc